Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
AssigneeLipocine Inc.
InventorsFeng-Jing Chen, Mahesh V. Patel, David T. Fikstad
Life of this patent
Estimating the term…
Loading patent…
AssigneeLipocine Inc.
InventorsFeng-Jing Chen, Mahesh V. Patel, David T. Fikstad
Estimating the term…
A delayed release pharmaceutical dosage form for oral administration of a hydrophilic drug, e.g., a polysaccharide drug such as low molecular weight heparin, are provided. The dosage form comprises a composition of: (a) a therapeutically effective amount of low molecular weight heparin; (b) a bile salt or bile acid; (c) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof; and a means for delaying release of the composition from the dosage form following oral administration. Osmotic drug delivery systems for oral administration of a hydrophilic drug are also provided, wherein an osmotically activated device houses the drug, a bile salt or bile acid, and at least one surfactant selected from the group consisting of hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. Methods for administering hydrophilic drugs, particularly polysaccharide drugs such as low molecular weight heparin, are also provided.
A delayed release pharmaceutical dosage form for oral administration of low molecular weight heparin comprising a composition of (a) a therapeutically effective amount of low molecular weight heparin, (b) a bile salt or a bile acid, (c) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, and (d) a means for delaying release of the composition from the dosage form following oral administration.
A delayed release dosage form for oral administration, comprised of a composition of low molecular weight heparin, a bile salt or acid, and at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, the composition coated with an enteric coating of a bioerodible, gradually hydrolyzable and/or gradually water-soluble coating.
A pharmaceutical composition comprised of a therapeutically effective amount of low molecular weight heparin, a bile salt or bile acid, at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, and a solubilizer.
A drug delivery system for oral administration of a polysaccharide drug, comprising:
A method for administering low molecular weight heparin to a patient, comprising orally administering to the patient a delayed release pharmaceutical dosage form comprising (a) a therapeutically effective amount of low molecular weight heparin;
A method for administering a polysaccharide drug to a patient, comprising orally administering to the patient:
A pharmaceutical dosage form for oral administration, comprising:
A delayed release pharmaceutical dosage form for oral administration of a polysaccharide drug, comprising a composition of:
A delayed release pharmaceutical dosage form comprising:
A delayed release pharmaceutical dosage form comprising:
Dependencies are inferred from the claim text.